The flavagline FL3 interferes with the association of Annexin A2 with the eIF4F initiation complex and transiently stimulates the translation of annexinA2 mRNA. Grindheim AK, Patil SS, Nebigil CG, Désaubry l, Vedeler A. Front. Cell Dev. Biol. 11: 1094941 (2023).

eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. Steinmann SM, Sánchez-Martín A, Tanzer E, Cigliano A, Pes GM, Simile MM, Désaubry L, Marin JJG, Evert M, Calvisi DF. Int. J. Mol. Sci. 24: 2055 (2023).

Flavaglines: discovery from plants used in traditional Chinese medicine, synthesis and drug development against cancer and immune disorders. Wang D., Tezeren M., Abou-Hamdan H., Yu P. Nebigil CG., Désaubry L. Curr. Chin.Chem. 2: e261121198321 (2022).

Flavagline synthetic derivative induces senescence in glioblastoma cancer cells without being toxic to healthy astrocytes. Harmouch E., Seitlinger J., Chaddad H., Barths J., Désaubry L., Grandemange S., Massfelder T., Ubeaud-Sequier G., Fuhrmann G., Fioretti F., Benkirane-Jessel N., Idoux-Gillet Y. Sci. Rep. 10: 13750 (2020).

Flavaglines as natural products targeting eIF4A and prohibitins: from traditional Chinese medicine to antiviral activity against coronaviruses. Nebigil CG, Moog C, Vagner S, Benkirane-Jessel N, Smith DR,  Désaubry L.  Eur. J. Med. Chem. 203: 112653 (2020).

Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma. Cerezo M., Guemiri R., Druillennec S., Girault I., Malka-Mahieu H., Shen S., Allard D., Martineau S., Welsch C., Agoussi S., Estrada C., Adam J., Libenciuc C., Routier E., Roy S., Désaubry L., Eggermont A.M., Sonenberg N., Scoazec J.Y., Eychène A., Vagner S., Robert C. Nature Med. 24: 1877-1886 (2018). Regulation of eIF4F translation initiation complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer. Garrido M.F., Martin N.J.P., Gaudin C., Commo F., Al Nakouzi N., Fazli L., Del Nery E., Camonis J., Perez F., Lerondel S., Gleave M., Loriot Y., Désaubry L., Vagner S., Fizazi K., Chauchereau A. Clin. Cancer Res. 25:710-723 (2018).

The mTOR-S6 kinase pathway promotes stress granule assembly. Sfakianos AP., Mellor LE., Pang YF., Kritsiligkou P., Needs H., Abou-Hamdan H., Désaubry L., Poulin GB., Ashe MP., Whitmarsh AJ. Cell. Death Dis. 25: 1766-1780 (2018).

CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. Tabet R., Schaeffer L., Freyermuth F., Jambeau M., Workman M., Lee C-Z., Lin C-C., Jiang J., Jansen-West K., Abou-Hamdan H, Désaubry L., Gendron T., Petrucelli L., Martin F., Lagier-Tourenne C. Nature Comm. 9: 152 (2018).

STAT1 Promotes KRAS Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A. Wang S, Darini C, Désaubry L, Koromilas AE. Mol Cancer Ther. 15: 3055-3063 (2016).

Molecular pathways: the eIF4F translation initiation complex –new opportunities for cancer treatment. Malka-Mahieu H., Newman M., Désaubry L., Robert C., Vagner S. Clin Cancer Res. 23: 21-25 (2016).

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. Malka-Mahieu H., Girault I., Rubington M., Leriche M., Welsch C., Kamsu-Kom N., Zhao Q., Désaubry L., Vagner S., Robert C. Cell cycle 15: 2405-2409 (2016).

Revision of the synthesis and pharmacological activity of a reported translation inhibitor. Basmadjian C., Malka-Mahieu H., Désaubry L. Anticancer Agents Med. Chem. 15: 1305-1307 (2015).eIF4F is a key and targetable convergence nexus of multiple resistance mechanisms to anti-RAF and anti-MEK cancer therapies. Boussemart L., Malka-Mahieu H., Girault I., Hemmingsson O., Allard D, Tomasic G., Thomas M., Ribeiro N., Thuaud F., Basmadjian C., Mateus C., Routier E., Kamsu-Kom N., Agoussi S., Eggermont A., Désaubry L., Robert C., Vagner S.  Nature 513: 105-9 (2014).